Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) rose 5.7% on Thursday . The company traded as high as $32.90 and last traded at $33.16. Approximately 397,700 shares were traded during trading, a decline of 71% from the average daily volume of 1,393,126 shares. The stock had previously closed at $31.38.
Wall Street Analyst Weigh In
A number of analysts recently commented on the stock. Needham & Company LLC restated a "buy" rating and issued a $90.00 price objective on shares of Vaxcyte in a research report on Tuesday, April 8th. The Goldman Sachs Group lowered their price target on Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Bank of America cut their price objective on Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Evercore ISI raised Vaxcyte to a "strong-buy" rating in a research note on Monday, March 31st. Finally, Guggenheim reiterated a "buy" rating and issued a $160.00 price target on shares of Vaxcyte in a report on Wednesday, March 12th. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Vaxcyte currently has an average rating of "Buy" and a consensus target price of $136.50.
Read Our Latest Stock Report on PCVX
Vaxcyte Price Performance
The stock's 50-day moving average price is $34.33 and its 200 day moving average price is $66.59. The firm has a market cap of $4.52 billion, a P/E ratio of -7.61 and a beta of 1.27.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same period in the previous year, the company earned ($0.85) EPS. As a group, analysts forecast that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the stock. Wells Fargo & Company MN grew its stake in shares of Vaxcyte by 53.7% in the fourth quarter. Wells Fargo & Company MN now owns 72,275 shares of the company's stock valued at $5,916,000 after buying an additional 25,257 shares in the last quarter. TimesSquare Capital Management LLC grew its position in shares of Vaxcyte by 53.7% in the 4th quarter. TimesSquare Capital Management LLC now owns 413,637 shares of the company's stock valued at $33,860,000 after acquiring an additional 144,516 shares during the period. Allspring Global Investments Holdings LLC increased its stake in shares of Vaxcyte by 70.8% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 593,523 shares of the company's stock worth $49,418,000 after purchasing an additional 246,049 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in shares of Vaxcyte by 188.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock worth $33,000 after purchasing an additional 260 shares during the last quarter. Finally, Rhumbline Advisers raised its holdings in shares of Vaxcyte by 4.7% in the 4th quarter. Rhumbline Advisers now owns 171,814 shares of the company's stock valued at $14,065,000 after purchasing an additional 7,711 shares during the period. 96.78% of the stock is currently owned by institutional investors.
Vaxcyte Company Profile
(
Get Free Report)
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
Further Reading
Before you consider Vaxcyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.
While Vaxcyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
